• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics
  • Business & Money
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview
      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Center for Psychedelic Medicine Established at NYU Langone Health

New Program Builds on Notable Achievements and Offers First-Ever Dedicated Training Program for Early Career Investigators in the Field

(PRNewsfoto/NYU School of Medicine)

News provided by

NYU Langone Health

Feb 24, 2021, 11:02 ET

Share this article

Share this article


NEW YORK, Feb. 24, 2021 /PRNewswire/ -- Philanthropic support from several donors totaling over $10 million will allow NYU Langone Health to advance its already world-renowned reputation in the field of psychedelic medicine through the establishment of a one-of-a-kind center dedicated to expanding research and professional medical training in this resurging field.  

When fully developed, the NYU Langone Center for Psychedelic Medicine, under the auspices of NYU Langone's Department of Psychiatry, will support health-focused research across the translational spectrum, from basic science to Phase III clinical trials. Principally, it will have three transdisciplinary areas of focus: psychiatry, medicine and preclinical research. In addition, a robust training program, the Psychedelic Medicine Research Training Program -- which differentiates this center from others – will support the development of early career faculty members and post-doctoral fellows to become independent investigators in the field of psychedelic medicine.

In addition, the Psychedelic Medicine Research Training Program aims to work with members of the psychedelic medicine industry to develop treatment models and training programs to help to scale psychedelic medicines into mainstream adoption by psychiatrists and therapists in America.

"These initiatives will provide an environment in which scientists, clinicians, trainees and other staff contribute in meaningful ways to ensure that the momentum created by the modern psychedelic renaissance is sustained and continues to yield medical breakthroughs backed by sound science," says Michael P. Bogenschutz, MD, Professor of Psychiatry at NYU Grossman School of Medicine, and an acknowledged leader in the field of psychedelic medicine who will serve as the Center's director.

Another unique aspect of the NYU Langone Center for Psychedelic Medicine is its commitment to move beyond the confines of psychiatry, expanding its focus into clinical applications across other health disciplines.

"Our broad focus on discovery for medical applications of psychedelics places NYU Langone at the vanguard of research on many difficult-to-treat psychiatric and medical disorders," says Stephen Ross, MD, associate professor of Psychiatry at NYU Grossman School of Medicine, and a fellow leader in the field who will serve as the Center's associate director. "Moreover, we plan to utilize this health-focused structure to provide important training opportunities to sustain high-quality psychedelic research."

Philanthropy Key to Expanding Psychedelic Research and Training

Principal funding for the Center comes from a consortium of individuals and organizations, all sharing a singular mission to advance the already groundbreaking work achieved in psychedelic medicine since its resurgence as a sub-specialty over the past 25 years.    

Leading the way is funding support of $5 million from MindMed, a neuro-pharmaceutical company pioneering new ways to treat mental health disorders through the advancement of both non-hallucinogenic and hallucinogenic compounds. Specifically, it will help to establish a psychedelic-based training program for clinical investigators skilled in the study of psychedelic-inspired treatments for serious mental health needs. This gift will provide salary support, training and pilot research funds for four positions (two junior faculty and two post-doctoral fellows) over the course of five years.

"We are honored and excited to help establish this first-of-its-kind training program at NYU Langone, which we believe will yield benefits to the overall advancement of psychedelic-inspired medicines in solving some of the most prevalent issues in mental health for patients," said JR Rahn, co-founder and chief executive officer of MindMed. "Few clinicians and institutions like NYU Langone Health and NYU Grossman School of Medicine are capable of conducting clinical research with psychedelic-inspired medicines. The need to train the next generation of investigators, and ultimately the entire psychiatry community in America, is critical to MindMed's mission of alleviating mental health with the use of psychedelics in the American mental healthcare system."

The remainder of support to establish the Center will come from a $1 million gift from business leader and philanthropist Carey Turnbull, as well as from several seven-figure gifts that he galvanized from his network. He is president of the Heffter Research Institute, one of the country's leading non-profit organizations dedicated to supporting studies on hallucinogens like psilocybin for treatment of mental health and other disorders. NYU Langone and the Heffter Institute, through Turnbull's support, enjoy a long and successful partnership in psychedelic research.

"It is my pleasure to join with others in supporting NYU Langone Health's extraordinary efforts in the field of psychedelic medicine," said Turnbull. "Our organization truly believes that there are significant advancements that will come out of further examination and clinical trial work in this field, and are excited to direct our support behind it."

Other major gifts to support the NYU Langone Center for Psychedelic Medicine include:

  • $2 million from Alan Fournier, a private investor and founder of Pennant Investors, LLC, with a history of support for psychedelic research and clinical trial activity
  • $1 million from Bill Linton, board member and president of the Usona Institute, a non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to further the understanding of the therapeutic effects of psilocybin and other consciousness-expanding medicines
  • Other significant donors include the George Sarlo Foundation, Cody Swift of the Riverstyx Foundation and Dr. Bronner's Soaps

Building on a Legacy of Groundbreaking Work

The NYU Langone Center for Psychedelic Medicine will serve as the hub for NYU Langone's continuing efforts in psychedelics – work that already has garnered international acclaim, and which has been a major force in the field's successful resurgence. Past and current research focuses principally on the treatment of advanced cancer-related psychiatric and existential distress, addiction, major depression and posttraumatic stress disorder (PTSD). Among the initiatives underway in psychedelic medicine at NYU Langone:

  • Dr. Bogenschutz is nearing completion as lead investigator of a Phase II clinical trial, sponsored by the Heffter Research Institute, examining the use of psilocybin to treat alcohol use disorder (AUD), and is developing a Phase II/III trial, sponsored by B.More (a philanthropic foundation led by Turnbull) with input from the US Food & Drug Administration.
  • Dr. Ross was the lead investigator on a landmark 2016, double-blind, placebo-controlled Phase II study suggesting a role for psilocybin-assisted psychotherapy to treat anxiety and depression in cancer patients. A follow-up, multisite Phase III study is in development and a funding proposal to support additional research in this area is under review with the National Cancer Institute.
  • Recruitment is currently underway for a Phase II study to evaluate the efficacy of a single dose of psilocybin in the context of brief supportive "set and setting" therapy for individuals with major depressive disorder (MDD). If the results of this study provide evidence of safety and efficacy, a Phase III study will be conducted under the "breakthrough therapy" designation supported by the FDA.
  • NYU Langone recently completed a Phase III study on the safety and efficacy of psychotherapy utilizing methylenedioxy-methamphetamine (MDMA) for the treatment of severe PTSD, and has begun recruitment for a second Phase III study.

Other studies are examining and/or plan to examine the use of psychedelics/hallucinogens for disorders including chronic pain management, end-of-life psychotherapy, opioid use disorder and smoking cessation, to name a few.

"Drs. Bogenschutz and Ross have assembled outstanding scientific and clinical teams to carry out completed, ongoing and proposed psychedelic-focused studies at NYU Langone Health," says Charles R. Marmar, MD, the Lucius Littauer Professor and Chair of the Department of Psychiatry.  "The infrastructure, support and training opportunities under the auspices of this new Center will springboard our psychedelic researcher efforts to new heights. We are very excited about what the future holds."

Media Inquiries:
Jim Mandler
NYU Langone Health
Office: (212) 404-3525 / Cell: (347) 714-3768
[email protected]

SOURCE NYU Langone Health

Related Links

http://www.med.nyu.edu

Modal title

Also from this source

Cancer-Killing Virus Therapy Shows Promise Against Inoperable...

Cancer-Killing Virus Therapy Shows Promise Against Inoperable...


Cancer-Killing Virus Therapy Shows Promise Against Inoperable...

Cancer-Killing Virus Therapy Shows Promise Against Inoperable...

Explore

More news releases in similar topics

  • Back-to-School Season
  • Education
  • Medical Pharmaceuticals
  • Health Care & Hospitals
  • New Products & Services

    Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

    About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement

    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2021 Cision US Inc.